Primary Job Title Co-Founder Primary Organization BioEclipse Therapeutics
Location East Lansing, Michigan, United States Regions Great Lakes, Midwestern US Gender Male
Website med.stanford.edu/profiles/christopher-contag LinkedIn View on LinkedIn
Dr. Contag, is a Professor in the Departments of Pediatrics, Radiology and Microbiology & Immunology at Stanford University, and a member of the BioX Faculty for interdisciplinary sciences, and the Immunology Faculty. Dr. Contag received his B.S. in Biology from the University of Minnesota, St. Paul in 1982. He received his Ph.D. in
Microbiology from the University of Minnesota, Minneapolis in 1988 where he did his dissertation research on the topic of viral infections of the central nervous system.
He was a postdoctoral fellow at Stanford University from 1990-1994 in the Department of Microbiology where he studied mother-to-infant transmission of HIV, and then joined the faculty in Pediatrics at Stanford in 1995 with a joint appointment in Microbiology and Immunology and a courtesy appointment in Radiology.
Dr. Contag is the Associate Chief of the Division of Neonatal and Developmental Medicine, director of Stanford’s Center for Innovation in In Vivo Imaging (SCI3) and co-director of the Molecular Imaging Program at Stanford (MIPS). Dr. Contag is a founding member, and past president of the Society for Molecular Imaging (now the World Molecular Imaging Society, WMIS), and for his fundamental contributions in imaging, is a recipient of the Achievement Award from the Society for the Molecular Imaging and is a Fellow and president elect of WMIS.
The research mission of the Contag laboratory is to develop and use noninvasive imaging tools that can simultaneously reveal the nuances of biological processes and provide an overall picture of disease states for the purpose of developing and refining novel interventions. These imaging tools are sensitive and image over a range of scales from micro- to macroscopic, and are well-suited for the in vivo study of cellular and molecular biology.
The Contag group is developing, and using, advanced microscopic tools with the aims of detecting and studying cancer at high resolution in vivo. These approaches use micro-optics to develop miniaturized microscopes that can reach inside the body to interrogate disease states. This is enabling point-of-care microscopy that is changing the diagnostic paradigm from biopsy and histopathology to in vivo pathology.
